Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin-to-skin Clear all
Completed Phase 2 Interventional Results available

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

NCT01118091
View directory record Official record
Conditions
Skin Cancer, Melanoma, Metastatic Melanoma
Interventions
Aldesleukin, CD8 enriched Young TIL
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI

NCT00891774
View directory record Official record
Conditions
Non Therapeutic Body Modification
Interventions
EVOLENCE®
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
11
States / cities
Los Angeles, California • Rancho Mirage, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
infliximab, Placebo Comparator
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
16 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Oct 11, 2026, 10:58 AM EDT
Terminated No phase listed Observational

A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings

NCT00581217
View directory record Official record
Conditions
Burns
Interventions
Aquacel Ag, Glucan II
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 11, 2026, 10:58 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Roseville, California • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

Microbiome and Association With Implant Infections

NCT05020574
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Genetic Predisposition to Disease
Interventions
Cephalexin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 11, 2026, 10:58 AM EDT
Recruiting Phase 1 Interventional

Naltrexone and Propranolol Combined With Immunotherapy

NCT05968690
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Propranolol, Naltrexone
Drug
Lead sponsor
Sarah Weiss
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591
View directory record Official record
Conditions
Erythemato-telangiectatic Rosacea
Interventions
BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

NCT00728949
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 11, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 11, 2026, 10:58 AM EDT
Terminated Phase 1Phase 2 Interventional

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

NCT05154890
View directory record Official record
Conditions
Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
Interventions
Pegtarviliase IV, Pegtarviliase SC
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 11, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00002826
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, valspodar
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
9
States / cities
Palo Alto, California • Stanford, California • Flemington, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 11, 2026, 10:58 AM EDT
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
View directory record Official record
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991
View directory record Official record
Conditions
Skin Aging
Interventions
Placebo, Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 11, 2026, 10:58 AM EDT
Recruiting No phase listed Observational

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

NCT07214610
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Structured behavioral intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
20 Years to 74 Years · Female only
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2044
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

NCT03025308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
2,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
72
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Study to Assess VB-201 in Patients With Psoriasis

NCT01001468
View directory record Official record
Conditions
Active Plaque Psoriasis
Interventions
VB-201, Placebo
Drug · Other
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Boston, Massachusetts • Haverhill (Boston), Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 11, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional

A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials

NCT07040891
View directory record Official record
Conditions
Breast Cancer
Interventions
Just ASK training
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation

NCT05565820
View directory record Official record
Conditions
Pediculosis Capitis, Lice Infestations, Head Lice
Interventions
Vamousse Spray 'n' Go, Nix Creme Rinse Lice Treatment
Other · Drug
Lead sponsor
Alliance Pharmaceuticals
Industry
Eligibility
2 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 11, 2026, 10:58 AM EDT
Not listed Phase 4 Interventional

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

NCT04214197
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Top Oint
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

NCT01300052
View directory record Official record
Conditions
Psoriasis
Interventions
AN2728 ointment, 2%, Ointment Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Fridley, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 11, 2026, 10:58 AM EDT
Completed Phase 1Phase 2 Interventional

Analyzing the Composition of Tears to Identify Cancer

NCT00574678
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Benign Disease
Interventions
Tear collection
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 11, 2026, 10:58 AM EDT